Professor Zhang Zhan commented on domestic CDK4/6 inhibitors: bring high -quality long survival to patients with HR positive breast cancer

On July 1, the "Top Ten Progress in the Cancer Field of the Public Public Most Incurities in 2021" was launched in "I do practical practice activities for the masses · Healthy Chinese Oncology Prevention and Control (2022-2023) and" Tumor's Things "column launched The launching ceremony was officially released.

(The above comments are from the chief physician of the Department of Internal Medicine of the Cancer Hospital of the Chinese Academy of Medical Sciences, and the deputy chairman of the Department of Internal Medicine of the Beijing Breast Disease Control Society)

Darcilla is the CDK4/6 inhibitor independently developed by China. Its listing fills the gap in my country's lack of independent innovative drugs in this field. Darcily's curative effect is quite or better than similar drugs abroad. Its listing has improved the availability of Chinese patients;

DAWNA-1 research group population is more suitable for the current status of diagnosis and treatment of Chinese patients. The research results have more clinical guiding significance for Chinese patients. At the same time, Darcille has good safety, especially in liver safety. It is hoped that Darcilla can be included in medical insurance as soon as possible, so that more patients will have the opportunity to use such a good medicine, so that the treatment of Chinese HR positive breast cancer is in line with international standards.

It is hoped that more new anti -tumor drugs can benefit patients, and more patients can benefit from standardized treatment.

- END -